Page 1644 - Williams Hematology ( PDFDrive )

1618 Part XI: Malignant Lymphoid Diseases Chapter 97: Hodgkin Lymphoma 1619

18. Gilbert R: Radiotherapy in Hodgkin’s disease (malignant granulomatosis): Anatomic highest in the Swedish Family-Cancer Database” by Altieri A and Hemminki K. Leuke-
and clinical foundations, governing principles, results. AJR Am J Roentgenol 41:198–241, mia 21:351, 2007.
1939. 51. Cimino G, Lo Coco F, Cartoni C, et al: Immune-deficiency in Hodgkin’s disease (HD):
19. Kaplan HS: The radical radiotherapy of regionally localized Hodgkin’s disease. Radiology A study of patients and healthy relatives in families with multiple cases. Eur J Cancer
78:553–561, 1962. Clin Oncol 24:1595–1601, 1988.
20. Goodman LS, Wintrobe MM, et al: Nitrogen mustard therapy; use of methyl-bis 52. Niens M, Jarrett RF, Hepkema B, et al: HLA-A*02 is associated with a reduced risk
(beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochlo- and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood
ride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscella- 110:3310–3315, 2007.
neous disorders. JAMA 132:126–132, 1946. 53. Kuppers R, Rajewsky K, Zhao M, et al: Hodgkin disease: Hodgkin and Reed-Sternberg
21. Jacobson LO, Spurr CL, et al: Nitrogen mustard therapy; studies on the effect of methyl-bis cells picked from histological sections show clonal immunoglobulin gene rearrange-
(beta-chloroethyl) amine hydrochloride on neoplastic diseases and allied disorders of ments and appear to be derived from B cells at various stages of development. Proc Natl
the hemopoietic system. JAMA 132:263–271, 1946. Acad Sci U S A 91:10962–10966, 1994.
22. Devita VT Jr, Serpick AA, Carbone PP: Combination chemotherapy in the treatment of 54. Kuppers R, Roers A, Kanzler H: Molecular single cell studies of normal and trans-
advanced Hodgkin’s disease. Ann Intern Med 73:881–895, 1970. formed lymphocytes. Cancer Surv 30:45–58, 1997.
23. Bonadonna G, Zucali R, Monfardini S, et al: Combination chemotherapy of Hodgkin’s 55. Bargou RC, Emmerich F, Krappmann D, et al: Constitutive nuclear factor-kappaB-RelA
disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J
MOPP. Cancer 36:252–259, 1975. Clin Invest 100:2961–2969, 1997.
24. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) 56. Jox A, Zander T, Kuppers R, et al: Somatic mutations within the untranslated regions of
Research Data (1973–2011), National Cancer Institute, DCCPS, Surveillance Research rearranged Ig genes in a case of classical Hodgkin’s disease as a potential cause for the
Program, Surveillance Systems Branch, released April 2014, based on the November absence of Ig in the lymphoma cells. Blood 93:3964–3972, 1999.
2013 submission; 2014. 57. Kanzler H, Kuppers R, Hansmann ML, et al: Hodgkin and Reed-Sternberg cells in
25. Clarke CA, Glaser SL, Keegan TH, et al: Neighborhood socioeconomic status and Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from
Hodgkin’s lymphoma incidence in California. Cancer Epidemiol Biomarkers Prev 14: (crippled) germinal center B cells. J Exp Med 184:1495–1505, 1996.
1441–1447, 2005. 58. Muschen M, Rajewsky K, Brauninger A, et al: Rare occurrence of classical Hodgkin’s
26. MacMahon B: Epidemiology of Hodgkin’s disease. Cancer Res 26:1189–1201, 1966. disease as a T cell lymphoma. J Exp Med 191:387–394, 2000.
27. Landgren O, Engels EA, Pfeiffer RM, et al: Autoimmunity and susceptibility to Hodgkin 59. Braeuninger A, Kuppers R, Strickler JG, et al: Hodgkin and Reed-Sternberg cells in
lymphoma: A population-based case-control study in Scandinavia. J Natl Cancer Inst lymphocyte predominant Hodgkin disease represent clonal populations of germinal
98:1321–1330, 2006. center-derived tumor B cells. Proc Natl Acad Sci U S A 94:9337–9342, 1997.
28. Grufferman S, Delzell E: Epidemiology of Hodgkin’s disease. Epidemiol Rev 6:76–106, 60. Marafioti T, Hummel M, Anagnostopoulos I, et al: Origin of nodular lymphocyte-
1984. predominant Hodgkin’s disease from a clonal expansion of highly mutated germinal-
29. Au WY, Gascoyne RD, Gallagher RE, et al: Hodgkin’s lymphoma in Chinese migrants center B cells. N Engl J Med 337:453–458, 1997.
to British Columbia: A 25-year survey. Ann Oncol 15:626–630, 2004. 61. Ohno T, Stribley JA, Wu G, et al: Clonality in nodular lymphocyte-predominant Hodg-
30. Katanoda K, Yako-Suketomo H: Comparison of time trends in Hodgkin and non kin’s disease. N Engl J Med 337:459–465, 1997.
-Hodgkin lymphoma incidence (1973–97) in East Asia, Europe and USA, from cancer 62. Schwering I, Brauninger A, Klein U, et al: Loss of the B-lineage-specific gene expres-
incidence in five continents Vol. IV–VIII. Jpn J Clin Oncol 38:391–393, 2008. sion program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood
31. Vianna NJ, Greenwald P, Davies JN: Extended epidemic of Hodgkin’s disease in high- 101:1505–1512, 2003.
school students. Lancet 1:1209–1211, 1971. 63. Re D, Muschen M, Ahmadi T, et al: Oct-2 and Bob-1 deficiency in Hodgkin and Reed
32. Kvale G, Hoiby EA, Pedersen E: Hodgkin’s disease in patients with previous infectious Sternberg cells. Cancer Res 61:2080–2084, 2001.
mononucleosis. Int J Cancer 23:593–597, 1979. 64. Stein H, Marafioti T, Foss HD, et al: Down-regulation of BOB.1/OBF.1 and Oct2 in clas-
33. Rosdahl N, Larsen SO, Clemmesen J: Hodgkin’s disease in patients with previous infec- sical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates
tious mononucleosis: 30 years’ experience. Br Med J 2:253–256, 1974. with immunoglobulin transcription. Blood 97:496–501, 2001.
34. Mueller N, Evans A, Harris NL, et al: Hodgkin’s disease and Epstein-Barr virus. Altered 65. Ushmorov A, Leithauser F, Sakk O, et al: Epigenetic processes play a major role in
antibody pattern before diagnosis. N Engl J Med 320:689–695, 1989. B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 107:2493–2500,
35. Alexander FE, Lawrence DJ, Freeland J, et al: An epidemiologic study of index and fam- 2006.
ily infectious mononucleosis and adult Hodgkin’s disease (HD): Evidence for a specific 66. Cobaleda C, Schebesta A, Delogu A, et al: Pax5: The guardian of B cell identity and
association with EBV+ve HD in young adults. Int J Cancer 107:298–302, 2003. function. Nat Immunol 8:463–470, 2007.
36. Hjalgrim H, Askling J, Rostgaard K, et al: Characteristics of Hodgkin’s lymphoma after 67. Foss HD, Reusch R, Demel G, et al: Frequent expression of the B-cell-specific activator
infectious mononucleosis. N Engl J Med 349:1324–1332, 2003. protein in Reed-Sternberg cells of classical Hodgkin’s disease provides further evidence
37. Ambinder RF, Browning PJ, Lorenzana I, et al: Epstein-Barr virus and childhood Hodg- for its B-cell origin. Blood 94:3108–3113, 1999.
kin’s disease in Honduras and the United States. Blood 81:462–467, 1993. 68. Mathas S, Janz M, Hummel F, et al: Intrinsic inhibition of transcription factor E2A by
38. Armstrong AA, Alexander FE, Cartwright R, et al: Epstein-Barr virus and Hodgkin’s HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin
disease: Further evidence for the three disease hypothesis. Leukemia 12:1272–1276, lymphoma. Nat Immunol 7:207–215, 2006.
1998. 69. Jundt F, Acikgoz O, Kwon SH, et al: Aberrant expression of Notch1 interferes with the
39. Glaser SL, Lin RJ, Stewart SL, et al: Epstein-Barr virus-associated Hodgkin’s disease: B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia
Epidemiologic characteristics in international data. Int J Cancer 70:375–382, 1997. 22:1587–1594, 2008.
40. Herndier BG, Sanchez HC, Chang KL, et al: High prevalence of Epstein-Barr virus in 70. Kumano K, Chiba S, Shimizu K, et al: Notch1 inhibits differentiation of hematopoietic
the Reed-Sternberg cells of HIV-associated Hodgkin’s disease. Am J Pathol 142:1073–1079, cells by sustaining GATA-2 expression. Blood 98:3283–3289, 2001.
1993. 71. Dukers DF, van Galen JC, Giroth C, et al: Unique polycomb gene expression pattern
41. Biggar RJ, Jaffe ES, Goedert JJ, et al: Hodgkin lymphoma and immunodeficiency in in Hodgkin’s lymphoma and Hodgkin’s lymphoma-derived cell lines. Am J Pathol
persons with HIV/AIDS. Blood 108:3786–3791, 2006. 164:873–881, 2004.
42. Powles T, Robinson D, Stebbing J, et al: Highly active antiretroviral therapy and the 72. Scheeren FA, Diehl SA, Smit LA, et al: IL-21 is expressed in Hodgkin lymphoma and
incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol activates STAT5: Evidence that activated STAT5 is required for Hodgkin lymphoma-
27:884–890, 2009. genesis. Blood 111:4706–4715, 2008.
43. Mack TM, Cozen W, Shibata DK, et al: Concordance for Hodgkin’s disease in identical 73. Marafioti T, Hummel M, Foss HD, et al: Hodgkin and Reed-Sternberg cells represent
twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J an expansion of a single clone originating from a germinal center B-cell with functional
Med 332:413–418, 1995. immunoglobulin gene rearrangements but defective immunoglobulin transcription.
44. Chang ET, Smedby KE, Hjalgrim H, et al: Family history of hematopoietic malignancy Blood 95:1443–1450, 2000.
and risk of lymphoma. J Natl Cancer Inst 97:1466–1474, 2005. 74. Joos S, Kupper M, Ohl S, et al: Genomic imbalances including amplification of
45. Ferraris AM, Racchi O, Rapezzi D, et al: Familial Hodgkin’s disease: A disease of young the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60:549–552,
adulthood? Ann Hematol 74:131–134, 1997. 2000.
46. Goldin LR, Pfeiffer RM, Gridley G, et al: Familial aggregation of Hodgkin lymphoma 75. Weniger MA, Melzner I, Menz CK, et al: Mutations of the tumor suppressor gene
and related tumors. Cancer 100:1902–1908, 2004. SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear
47. Hemminki K, Li X, Czene K: Familial risk of cancer: Data for clinical counseling and phospho-STAT5 accumulation. Oncogene 25:2679–2684, 2006.
cancer genetics. Int J Cancer 108:109–114, 2004. 76. Barth TF, Martin-Subero JI, Joos S, et al: Gains of 2p involving the REL locus correlate
48. Altieri A, Hemminki K: The familial risk of Hodgkin’s lymphoma ranks among the with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lym-
highest in the Swedish Family-Cancer Database. Leukemia 20:2062–2063, 2006. phoma. Blood 101:3681–3686, 2003.
49. Grufferman S, Cole P, Smith PG, et al: Hodgkin’s disease in siblings. N Engl J Med 77. Cabannes E, Khan G, Aillet F, et al: Mutations in the IkBa gene in Hodgkin’s disease
296:248–250, 1977. suggest a tumour suppressor role for IkappaBalpha. Oncogene 18:3063–3070, 1999.
50. Horwitz MS, Mealiffe ME: Further evidence for a pseudoautosomal gene for Hodg- 78. Emmerich F, Theurich S, Hummel M, et al: Inactivating I kappa B epsilon mutations in
kin’s lymphoma: Reply to “The familial risk of Hodgkin’s lymphoma ranks among the Hodgkin/Reed-Sternberg cells. J Pathol 201:413–420, 2003.

Kaushansky_chapter 97_p1603-1624.indd 1619 9/18/15 11:12 PM